Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Nuvation Bio Inc.NYSE: NUVB

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables rises 375.0% from a year ago

Net receivables stood at $31.71M at the end of Q2 FY2026, up 375.0% from a year earlier and up 22.1% from the prior quarter. Over 3 fiscal years it compounded at +98.2% a year.

Context

  • Net receivables amounted to 4.3% of total assets at the end of Q2 FY2026, up 3.2 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +375.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$31.71M+22.1% QoQ
Last fiscal yearDec 2025
$19.36M+18.8% YoY
Year agoJun 2025
$6.68M+375.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+375.0%——
1 year+18.8%——
3-year CAGR+98.2%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
19.36M USD
Year-over-year change
+18.8%
4-year CAGR
+58.9%

Net Receivables vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's Jun 2026 net receivables of $31.71M is the 5th highest of the 11 companies compared; the peer median is $13.95M.
  • Its year-over-year change of +375.0% is the 2nd highest of 8, against a peer median of +2.6%.
  • Net receivables amounts to 4.3% of total assets for NUVB, versus a peer median of 1.9%.
NUVB Competitors Peer median
Net Receivables for NUVB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VRDNViridian Therapeutics, Inc.Jun 2026$75M ——6.8%
ABCLAbCellera Biologics Inc.Sep 2026$67.28M -57.8%+14.0%4.5%
JANXJanux Therapeutics, Inc.Mar 2026$42.46M +660.3%+109.4%4.1%
AUPHAurinia Pharmaceuticals Inc.Jun 2026$41.14M +2.6%+45.4%5.2%
NUVBNuvation Bio Inc.Jun 2026$31.71M +375.0%+98.2%4.3%
OCULOcular Therapeutix, Inc.Mar 2026$24.35M -3.5%+12.9%3.3%
QUREuniQure N.V.Mar 2026$3.56M +41.2%-61.5%0.5%
CLDXCelldex Therapeutics, Inc.Sep 2026$355K +294.4%+79.7%0.0%
EWTXEdgewise Therapeutics, Inc.Sep 2026$0 ——0.0%
VERAVera Therapeutics, Inc.Jun 2026$0 -100.0%—0.0%
GPCRStructure Therapeutics Inc.Jun 2026$0 ——0.0%
Peer median (excluding NUVB) $13.95M+2.6%+29.7%1.9%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.42M101.1M42.65M35.72M164.09M
Short-term Investments632.97M559.92M568.56M466.97M365.13M
Net Receivables3.04M2.49M3.7M16.29M19.36M
Inventory000011.41M
Other Current Assets03.82M1.52M7.27M11.54M
Total Current Assets772.07M667.32M616.43M526.26M571.52M
Property, Plant & Equipment (Net)3.66M4.69M4.32M2.99M4.48M
Goodwill00000
Intangible Assets0004.62M11.21M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets421K138K728K6.76M7.61M
Total Non-current Assets4.08M4.82M5.05M14.37M23.3M
Total Assets776.15M672.14M621.48M540.63M594.82M
Account Payables3.93M2.14M2.21M6.35M9.48M
Short-term Debt0006.28M7.6M
Tax Payables402K112K144K679K0
Deferred Revenue00011.12M0
Other Current Liabilities6.17M3.99M4.35M14.82M65.15M
Total Current Liabilities16.93M13.16M13.97M58.24M82.23M
Long-term Debt00002.54M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00015.57M145.82M
Other Non-current Liabilities11.04M850K353K2.05M58.51M
Total Non-current Liabilities13.23M3.9M2.39M18.59M206.88M
Total Liabilities30.15M17.07M16.36M76.84M289.11M
Common Stock909.99M927.6M947.75M1.37B1.42B
Retained Earnings(162.8M)(267M)(342.8M)(910.74M)(1.12B)
Accumulated OCI(1.19M)(5.53M)181K573K(187K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity746M655.08M605.12M463.79M305.72M
Total Debt3.06M4.26M4.01M8.92M10.15M
Net Debt(129.37M)(96.84M)(38.64M)(26.81M)(153.94M)

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.